Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139776 · ClinicalTrials.gov registry record · Phase 4
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 875
- Enrollment target
NCT00139776: Completed Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00139776 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 875 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00139776, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 875 participants
- Enrollment target
Study Summary
To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.
Primary Outcome
Number of flare events per month during Period III (calculated as number of flares divided by number of months participant was enrolled during Period III). Flare was determined using pre-defined criteria, using an interactive voice response system.
Interventions
- DRUG Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 875 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-02 |
| Phase | Phase 4 |
What the finished NCT00139776 record still lists
NCT00139776 is an interventional study that assigns participants to a tested intervention. The registered 875 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% higher).
The record links to 0 conditions, and to 1 intervention - of which Celecoxib is the first listed.
NCT00139776 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00139776 about?
NCT00139776 is a clinical study titled "Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"". To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.
What is the current status of trial NCT00139776?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 875 participants. The study started on 2005-07. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00139776?
The interventions under investigation include: Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00139776?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00139776's enrollment target sits among peer trials
875 87th of 2000 higher than 1,914 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07076199 · 877 participants · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- NCT06627647 · 878 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia